Orchestra BioMed Holdings (OBIO) Cash from Operations (2021 - 2026)

Orchestra BioMed Holdings (OBIO) has 6 years of Cash from Operations data on file, last reported at 22168000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations fell 33.41% year-over-year to 22168000.0 in Q1 2026; TTM through Mar 2026 was 54515000.0, a 0.84% decrease from a year earlier, with the FY2025 full-year figure at 48963000.0, up 3.15% from the prior year.
• Cash from Operations for Q1 2026 stood at 22168000.0, down from 2270000.0 in the prior quarter.
• Over the last five years, Cash from Operations for OBIO reached as high as 2270000.0 in Q4 2025 and fell as low as 22168000.0 in Q1 2026.
• Historically, Cash from Operations has averaged 11594411.76 across 5 years, with a median of 10974000.0 in 2023.
• Across the five-year window, Cash from Operations sank 30224.26% in 2022 and jumped 83.23% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 8744000.0 in 2022, then decreased by 25.5% to 10974000.0 in 2023, then declined by 23.36% to 13538000.0 in 2024, then soared by 83.23% to 2270000.0 in 2025, then tumbled by 876.56% to 22168000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 22168000.0 in Q1 2026, 2270000.0 in Q4 2025, and 14550000.0 in Q3 2025.